Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera

British Journal of Cancer

Volumn 90, Issue 7, 2004, Pages 1414-1421

  La Rocca, G ^a   Pucci Minafra, I ^a,c   Marrazzo, A ^a,b   Taormina, P ^b   Minafra, S ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Casa di Cura di Alta Specialita L   (Italy)

^c Dipto Oncol Sperim A   (Italy)

Author keywords

Breast cancer; Clinic correlations; Gelatin zymography; Matrix metalloproteinases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; GELATINASE B;

ARTICLE; BODY FLUID; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DENSITOMETRY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURFACE PROPERTY; TUMOR VOLUME; ZYMOGRAPHY;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 2342487379     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601725     Document Type: Article

References (36)

1. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM (2000) c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol 18: 2201-2209
2. Berney CR, Yang J, Fisher RJ, Russell PJ, Crowe PJ (1998) Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression. Oncol Res 10: 47-54
3. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943
4. Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
5. Diamandis EP, Yousef GM (2002) Human tissue kallikreins: a family of new cancer biomarkers. Clin Chem 48: 1198-1205
6. Dickson RB, Lippman ME (1995) Growth factors in breast cancer. Endocr Rev 16: 559-589
7. Duffy MJ (1996) The biochemistry of metastasis. Adv Clin Chem 32: 136-166
8. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N (2000) Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2: 252-257
9. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW, Davidge ST (1999) Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 82: 1730-1735
10. Garbett EA, Reed MW, Brown NJ (1999) Proteolysis in human breast and colorectal cancer. Br J Cancer 81: 287-293
11. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson WG, Liotta LA (1992) Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52: 4548-4549
12. Giunciuglio D, Culty M, Fassina G, Masiello L, Melchiori A, Paglialunga G, Arand G, Ciardiello F, Basolo F, Thompson EW, Albini A (1995) Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 63: 815-822
13. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn H-J (2001) Meeting highlights: International consensus panel on treatment of primary breast cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19: 3817-3827
14. Hayasaka A, Suzuki N, Fujimoto N, Iwama S, Fukuyama E, Kanda Y, Saisho H (1996) Elevated plasma levels of matrix metalloproteinase-9 92-kD type IV collagenase-gelatinase B in hepatocellular carcinoma. Hepatology 24: 1058-1062
15. Hirvonen R, Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T (2003) Matrix metalloproteinase-2 (MMP-2) in T(1-2) N0 breast carcinoma. Breast Cancer Res Treat 77: 85-91
16. Jung K, Lein M, Laube C, Lichtinghagen R (2001) Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 314: 241-244
17. Jung K, Lein M, Roemer A, Lichtinghagen R (2002) Circulating gelatinase B (MMP-9) - the impact of the preanalytical step of blood collection: RE: Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophoresis. Matrix Biol 21: 381-382
18. Kaya M, Yoshida K, Higashino F, Mitaka T, Ishii S, Fujinaga K (1996) A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells. Oncogene 12: 221-227
19. Keller KM, Keller JM, Kuhn K (1986) The C-terminus of type I collagen is a major binding site for heparin. Biochim Biophys Acta 882: 1-5
20. King J, Zhao J, Clingan P, Morris D (2003) Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 23: 639-645
21. Konecny G, Untch M, Arboleda J, Wilson C, Kahlert S, Boettcher B, Felber M, Beryt M, Lude S, Hepp H, Slamon D, Pegram M (2001) HER-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer. Clin Cancer Res 7: 2448-2457
22. Leeman MF, Curran S, Murray GI (2003) New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201: 528-534
23. Moura-da-Silva AM, Theakston RDG, Crampton JM (1996) Evolution of disintegrin cysteine-rich and mammalian matrix-degrading metalloproteinases: gene duplication and divergence of a common ancestor rather than convergent evolution. J Mol Evol 43: 263-269
24. Murphy G, Nguyen Q, Cockett MI, Atkinson SJ, Allan JA, Knight CG, Willenbrock F, Docherty AJ (1994) Assessment of the role of the fibronectin-like domain of gelatinase A by analysis of a deletion mutant. J Biol Chem 269: 6632-6636
25. Nagase H, Woessner Jr JF (1999) Matrix metalloproteinases. J Biol Chem 274: 21491-21494
26. Oberg A, Hoyhtya M, Tavelin B, Stenling R, Lindmark G (1999) Limited value of preoperative serum analyses of matrix metalloproteinases MMP-2, MMP-9 and tissue inhibitors of matrix metalloproteinases TIMP-1, TIMP-2 in colorectal cancer. Gut 45: 252-258
27. O'Shea C, McKie N, Buggy Y, Duggan C, Hill AD, McDermott E, O'Higgins N, Duffy MJ (2003) Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 105(6): 754-761
28. Overall CM, King AE, Sam DK, Ong AD, Lau TT, Wallon UM, DeClerk YA, Attherstone J (1999) Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV. J Biol Chem 274: 4421-4429
29. Pucci-Minafra I, Minafra S, La Rocca G, Barranca M, Fontana S, Alaimo G, Okada Y (2001) Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophoresis. Matrix Biol 20: 419-427
30. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L (2003) Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 106: 745-751
31. Sahin AA (2000) Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv Anat Pathol 7: 158-166
32. Somerville RPT, Oblander SA, Apte SS (2003) Matrix metalloproteinases: old dogs with new tricks. Genome Biol 4(6): 216
33. Stetler-Stevenson WG (1990) Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 9: 289-303
34. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-535
35. 2+ for fibronectin and heparin binding. J Biol Chem 272: 7473-7481
36. Zucker S, Lysik RM, Zarrabi MH, Moll U (1993) Mr 92 000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 53: 140-146